Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114684 | 0.92 | CDK5 (0.31) | MAPK14 | |
| SCHEMBL3124399 | 0.85 | RAB9A (0.32) | HCRTR1HCRTR2 | |
| SCHEMBL3118605 | 0.84 | HTR2C (0.36) | HCRTR1HCRTR2 | |
| SCHEMBL3113159 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3113599 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3113114 | 0.83 | MAPK14 (0.33) | MAPK14 | |
| SCHEMBL3835719 | 0.80 | MAPT (0.32) | — | |
| SCHEMBL3835721 | 0.80 | MAPT (0.32) | — | |
| SCHEMBL3835724 | 0.80 | MAPT (0.32) | — | |
| SCHEMBL1265295 | 0.78 | ALDH1A1 (0.33) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | claimed |
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-15 | — | — | US | disclosed |
| EP-2099805-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB Pharma S.A. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008064829-A2 | NOVEL AMINOTHIENOPYRIDINONE DERIVATIVES PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THEREOF | UCB PHARMA, S.A. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179185-A1 | Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof | AASDHPPT, PTMS, TPMT | MAPK14 3742/4885APLNR 656/4885HCRTR1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.